Why Big Pharma Is Hooked on Chinese Drug Licensing Deals Amid Rising Washington Scrutiny.
Multinational pharmaceutical giants—including Pfizer, AstraZeneca, AbbVie, Bristol Myers Squibb, and Merck—are rapidly shifting the front end of their innovation pipelines to Greater China. Cross-border out-licensing agreements signed between Western drugmakers and Chinese biotechnology firms surged to a record $137.7 billion, according to industry tracking data from PharmCube and Reuters. With 2026 deal values accelerating further, … Read more